dihydroethidium has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, D; Maghzal, GJ; Stocker, R; Talib, J | 1 |
| Bai, N; Granville, DJ; Hunter, AL; Laher, I | 1 |
2 other study(ies) available for dihydroethidium and Vascular Diseases
| Article | Year |
|---|---|
Detailed protocol to assess in vivo and ex vivo myeloperoxidase activity in mouse models of vascular inflammation and disease using hydroethidine.
Topics: Animals; Biomarkers; Chromatography, Liquid; Disease Models, Animal; Halogenation; Humans; Hydrogen Peroxide; Hypochlorous Acid; Inflammation; Mice; Oxidation-Reduction; Peroxidase; Phenanthridines; Tandem Mass Spectrometry; Tyrosine; Vascular Diseases | 2016 |
Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Endothelium, Vascular; Enzyme Inhibitors; Ethidium; Fluorescent Dyes; Heart; In Vitro Techniques; Ischemia; Male; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Steroid 21-Hydroxylase; Sulfaphenazole; Vascular Diseases | 2005 |